AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 22 min read$CYTK

Lee Sung sold $98K of CYTK

Lee Sung (EVP, Chief Financial Officer) sold 1,112 shares of CYTOKINETICS INC (CYTK) at $87.79 on 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lee Sung
Published Jul 2, 2026, 9:17 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 2, 2026, 9:21 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$CYTK
Neutral
medium confidence
Mentioned
$CYTK
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CYTKNeutralLow
01

Why it matters

The newest fact is the CFO’s open-market sale details (shares, price, total value) executed under a pre-arranged 10b5-1 plan; this is typically not a standalone fundamental driver.

02

Market read

Primarily useful for monitoring insider activity; unlikely to materially change valuation expectations by itself.

03

What to watch

The filing does not disclose intent beyond the plan; without context on prior sales cadence, it’s hard to infer directionality or conviction.

Relevance 2/10Novelty 4/10Timing: Filed after-hours on 2026-07-02; sale executed 2026-07-01.

Background

The article is a SEC Form 4 insider transaction disclosure for Cytokinetics, Inc. (CYTK).

Company-level read

Ticker impact

$CYTKNeutralMedium confidence
Context

CYTOK CFO Lee Sung filed a Form 4 showing an open-market sale of 1,112 shares at $87.79 on 2026-07-01 under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect is more sentiment/positioning than fundamentals.

Evidence & confidence

The filing is a primary-source Form 4, but it is explicitly tied to a pre-arranged 10b5-1 plan and the disclosed size ($~98K) is modest versus typical market-moving thresholds.

Market effects

Sector

No sector read-through; this is company-specific insider transaction data.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even with a 10b5-1 plan, repeated insider selling can still coincide with management’s near-term risk assessment; traders may watch for follow-on sales or changes in plan behavior.

Key entities

  • issuer
    CYTOKINETICS INC

    Company whose CFO insider sale was disclosed on Form 4.

  • insider
    Lee Sung

    EVP, Chief Financial Officer; reported an open-market sale under a 10b5-1 plan.

Read at source← All news

Related articles

AUG 6
$CYTKMedAI 8/10

CYTOKINETICS INC (CYTK): Results of Operations and Financial Condition

CYTOKINETICS INC (CYTK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cytk-ex99_1.htm EX-99.1 EX-99.1 Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update MYQORZO ® (aficamten) Net Product Revenue of $25 Million Full Results from ACACIA-HCM to be Presented in Hot Line Session at ESC; Expect to Submit Sup

SEC EDGAR 8-K6 min
JUL 30
$CYTKMedAI 8/10

Cytokinetics Secures MHRA Marketing Authorization For MYQORZO In OHCM

Cytokinetics (CYTK) said the UK MHRA granted marketing authorization for MYQORZO (aficamten) to treat adults with obstructive hypertrophic cardiomyopathy, NYHA class II-III. NICE issued positive guidance for eligible patients in England and Wales. Approval cited SEQUOIA-HCM Phase 3 results, with peak oxygen uptake improving vs placebo (1.8 vs 0.0 mL/kg/min, p<0.001).

rttnews.com4 min
JUL 30
$CYTKMedAI 8/10

Cytokinetics' cardiomyopathy drug cleared for NHS use

Cytokinetics said the UK MHRA and NICE cleared its cardiomyopathy drug Myqorzo (aficamten) for NHS use as an add-on to standard therapy in adults with NYHA class II-III obstructive hypertrophic cardiomyopathy. NICE required cost parity with Bristol Myers Squibb’s Camzyos. Myqorzo made about $5m in Q1 sales; Camzyos $314m.

pharmaphorum.com4 min
JUL 24
$CYTKMed

What Makes Cytokinetics' MYQORZO Launch a Game Changer

Cytokinetics (CYTK) is commercializing MYQORZO (aficamten), approved for symptomatic obstructive hypertrophic cardiomyopathy in the U.S., Europe, and China. The U.S. launch began in January 2026 and Europe is planned for Germany in Q2 2026. In 2025, revenue rose to $88.0M and net loss widened to $784.9M, while cash was about $1.22B.

kavout.com6 min
JUN 1
$CYTKMedAI 8/10

Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany

Cytokinetics (Nasdaq: CYTK) said MYQORZO® (aficamten) has launched commercially in Germany, the first European availability, for adults with symptomatic obstructive hypertrophic cardiomyopathy (NYHA II–III). The company cited EU approval in February 2026 based on SEQUOIA-HCM Phase 3 results, including a 1.76 mL/kg/min pVO2 improvement vs 0.0 with placebo over 24 weeks.

manilatimes.net4 min